[en] BACKGROUND: Medically managed tricuspid regurgitation (TR) has detrimental outcomes. Transcatheter tricuspid valve interventions (TTVIs) represent an alternative to surgery in high-risk patients; however, only early experiences exist. AIM: The aim of this study was to analyze the clinical and echocardiographic outcomes of TTVI. METHODS: MEDLINE, ISI Web of Science, and SCOPUS databases were searched for studies published up to June 2021. Studies reporting data on outcome post-TTVIs were included. This study was designed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) requirements. The primary endpoint was all-cause mortality at 30-day and 1-year post-TTVI. RESULTS: Out of 2,718 studies, 27 were included. Notably, 30-day and 1-year all-cause mortalities were 5% (95% confidence interval [CI]: 4-8%, p < 0.001) and 25% (95% CI: 12-45%, p = 0.016). Procedural success was associated with a 58% risk reduction in 1-year mortality vs. lack thereof (odds ratio 0.42, 95% CI: 0.27-0.66, p < 0.001). TTVI is associated with a significant reduction in TR severity (TR EROA, mean difference [MD] 0.31 cm(2); 95% CI: 0.23-0.39 cm(2), p < 0.001; regurgitant volume, MD 23.54 ml; 95% CI: 17.4-29.68 ml, p = 0.03) and increase in forward stroke volume (FSV, MD 3.98 ml; 95% CI: 0.11-7.86 ml, p = 0.04). CONCLUSION: TTVI significantly reduces TR severity and increases FSV and is associated with improved survival at 1 year compared with patients without procedural success. Long-term outcomes compared with medical therapy await the results of ongoing pivotal trials; nonetheless, TTVIs appear to be a promising alternative to surgery for TR.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Sannino, Anna; The Heart Hospital Baylor Plano, Plano, TX, United States. ; Department of Advanced Biomedical Sciences, University Federico II, Naples,
Ilardi, Federica; Department of Advanced Biomedical Sciences, University Federico II, Naples, ; Mediterranea Cardiocentro, Naples, Italy.
Hahn, Rebecca T; Division of Cardiology, Columbia University Irving Medical Center, New York, NY,
Lancellotti, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie ; Department of Cardiology and Radiology, GIGA Cardiovascular Sciences, CHU ; Gruppo Villa Maria Care and Research, Lugo, Italy.
Lurz, Philipp; Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of
Smith, Robert L; The Heart Hospital Baylor Plano, Plano, TX, United States.
Esposito, Giovanni; Department of Advanced Biomedical Sciences, University Federico II, Naples,
Grayburn, Paul A; The Heart Hospital Baylor Plano, Plano, TX, United States.
Language :
English
Title :
Clinical and Echocardiographic Outcomes of Transcatheter Tricuspid Valve Interventions: A Systematic Review and Meta-Analysis.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Otto CM Nishimura RA Bonow RO Carabello BA Erwin JP Gentile F et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. (2021) 143:e72–e227. 10.1161/CIR.000000000000092333332150
Vieitez JM Monteagudo JM Mahia P Perez L Lopez T Marco I et al. New insights of tricuspid regurgitation: a large-scale prospective cohort study. Eur Heart J Cardiovasc Imaging. (2020) 22:196–202. 10.1093/ehjci/jeaa20533704454
Muraru D Guta AC Ochoa-Jimenez RC Bartos D Aruta P Mihaila S et al. Functional regurgitation of atrioventricular valves and atrial fibrillation: an elusive pathophysiological link deserving further attention. J Am Soc Echocardiogr. (2020) 33:42–53. 10.1016/j.echo.2019.08.01631685293
Wang N Fulcher J Abeysuriya N McGrady M Wilcox I Celermajer D et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. (2019) 40:476–84. 10.1093/eurheartj/ehy64130351406
Vahanian A Beyersdorf F Praz F Milojevic M Baldus S Bauersachs J et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2021) 43:561–632. 10.1093/ejcts/ezac20935636831
Alqahtani F Berzingi CO Aljohani S Hijazi M Al-Hallak A Alkhouli M. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc. (2017) 6:e007597. 10.1161/JAHA.117.00759729273638
Dreyfus J Flagiello M Bazire B Eggenspieler F Viau F Riant E et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. (2020) 41:4304–17. 10.1093/eurheartj/ehaa64332974668
Nishimura RA Otto CM Bonow RO Carabello BA Erwin JP Fleisher LA et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. (2017) 135:e1159–e95. 10.1161/CIR.000000000000050328315732
Moher D Liberati A Tetzlaff J Altman DG Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. (2010) 8:336–41. 10.1016/j.ijsu.2010.02.00720171303
Taramasso M Alessandrini H Latib A Asami M Attinger-Toller A Biasco L et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv. (2019) 12:155–65. 10.1016/j.jcin.2018.10.02230594510
Sannino A Hahn RT Leipsic J Mack MJ Grayburn PA. Meta-analysis of incidence, predictors and consequences of clinical and subclinical bioprosthetic leaflet thrombosis after transcatheter aortic valve implantation. Am J Cardiol. (2020) 132:106–13. 10.1016/j.amjcard.2020.07.01832773221
Higgins JP Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. (2004) 23:1663–82. 10.1002/sim.175215160401
Ali FM Ong G Edwards J Connelly KA Fam NP. Comparison of transcatheter tricuspid valve repair using the MitraClip NTR and XTR systems. Int J Cardiol. (2021) 327:156–62. 10.1016/j.ijcard.2020.11.07333301831
Asmarats L Perlman G Praz F Hensey M Chrissoheris MP Philippon F et al. Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience. JACC Cardiovasc Interv. (2019) 12:1438–47. 10.1016/j.jcin.2019.04.03831395213
Besler C Orban M Rommel KP Braun D Patel M Hagl C et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. (2018) 11:1119–28. 10.1016/j.jcin.2018.05.00229929631
Braun D Orban M Orban M Hagl C Massberg S Nabauer M et al. Transcatheter edge-to-edge repair for severe tricuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique. JACC Cardiovasc Interv. (2018) 11:1790–2. 10.1016/j.jcin.2018.05.04930170957
Braun D Rommel KP Orban M Karam N Brinkmann I Besler C et al. Acute and short-term results of transcatheter edge-to-edge repair for severe tricuspid regurgitation using the MitraClip XTR system. JACC Cardiovasc Interv. (2019) 12:604–5. 10.1016/j.jcin.2018.11.02830898258
Cai S Bowers N Dhoot A Ho EC Ong G Eckstein J et al. Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy. Int J Cardiol. (2020) 320:49–54. 10.1016/j.ijcard.2020.07.01832682962
Campelo-Parada F Perlman G Philippon F Ye J Thompson C Bedard E et al. First-in-Man Experience of a Novel Transcatheter Repair System for Treating Severe Tricuspid Regurgitation. J Am Coll Cardiol. (2015) 66:2475–83. 10.1016/j.jacc.2015.09.06826653620
Davidson CJ Lim DS Smith RL Kodali SK Kipperman RM Eleid MF et al. Early Feasibility Study of Cardioband Tricuspid System for Functional Tricuspid Regurgitation: 30-Day Outcomes. JACC Cardiovasc Interv. (2021) 14:41–50. 10.1016/j.jcin.2020.10.01733413863
Dreger H Mattig I Hewing B Knebel F Lauten A Lembcke A et al. Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention. (2020) 15:1506–13. 10.4244/EIJ-D-19-0090131929100
Fam NP Braun D von Bardeleben RS Nabauer M Ruf T Connelly KA et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. (2019) 12:2488–95. 10.1016/j.jcin.2019.09.04631857018
Fam NP von Bardeleben RS Hensey M Kodali SK Smith RL Hausleiter J et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. (2021) 14:501–11. 10.1016/j.jcin.2020.11.04533582084
Hahn RT Kodali S Fam N Bapat V Bartus K Rodes-Cabau J et al. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation. JACC Cardiovasc Interv. (2020) 13:2482–93. 10.1016/j.jcin.2020.07.00833153565
Hahn RT Meduri CU Davidson CJ Lim S Nazif TM Ricciardi MJ et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. (2017) 69:1795–806. 10.1016/j.jacc.2017.01.05428385308
Kitamura M Fam NP Braun D Ruf T Sugiura A Narang A et al. 12-Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation. Catheter Cardiovasc Interv. (2021) 97:1281–9. 10.1002/ccd.2958333660364
Kodali S Hahn RT Eleid MF Kipperman R Smith R Lim DS et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. (2021) 77:345–56. 10.1016/j.jacc.2020.11.04733509390
Lauten A Figulla HR Unbehaun A Fam N Schofer J Doenst T et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv. (2018) 11:e006061. 10.1161/CIRCINTERVENTIONS.117.00606129445001
Lurz P Besler C Noack T Forner AF Bevilacqua C Seeburger J et al. Transcatheter treatment of tricuspid regurgitation using edge-to-edge repair: procedural results, clinical implications and predictors of success. EuroIntervention. (2018) 14:e290–e7. 10.4244/EIJ-D-17-0109129633941
Mehr M Taramasso M Besler C Ruf T Connelly KA Weber M et al. 1-Year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the trivalve registry. JACC Cardiovasc Interv. (2019) 12:1451–61. 10.1016/j.jcin.2019.04.01931395215
Nickenig G Kowalski M Hausleiter J Braun D Schofer J Yzeiraj E et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge mitraclip technique. Circulation. (2017) 135:1802–14. 10.1161/CIRCULATIONAHA.116.02484830927530
Nickenig G Weber M Lurz P von Bardeleben RS Sitges M Sorajja P et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. (2019) 394:2002–11. 10.1016/S0140-6736(19)32600-531708188
Nickenig G Weber M Schueler R Hausleiter J Nabauer M von Bardeleben RS et al. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol. (2019) 73:1905–15. 10.1016/j.jacc.2019.01.06230999993
Orban M Rommel KP Ho EC Unterhuber M Pozzoli A Connelly KA et al. Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail. (2020) 8:265–76. 10.1016/j.jchf.2019.12.00632241534
Perlman G Praz F Puri R Ofek H Ye J Philippon F et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv. (2017) 10:1994–2003. 10.1016/j.jcin.2017.06.03628780036
Perlman GY Dvir D. Treatment of tricuspid regurgitation with the FORMA repair system. Front Cardiovasc Med. (2018) 5:140. 10.3389/fcvm.2018.0014031395213
Rommel KP Besler C Noack T Blazek S von Roeder M Fengler K et al. Physiological and clinical consequences of right ventricular volume overload reduction after transcatheter treatment for tricuspid regurgitation. JACC Cardiovasc Interv. (2019) 12:1423–34. 10.1016/j.jcin.2019.02.04231326430
Ruf TF Hahn RT Kreidel F Beiras-Fernandez A Hell M Gerdes P et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv. (2021) 14:1231–40. 10.1016/j.jcin.2021.03.03334112460
Sugiura A Vogelhuber J Ozturk C Schwaibold Z Reckers D Goto T et al. PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis. Clin Res Cardiol. (2021) 110:451–9. 10.1007/s00392-020-01784-w33313975
Benfari G Antoine C Miller WL Thapa P Topilsky Y Rossi A. et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. (2019) 140:196–206. 10.1161/CIRCULATIONAHA.118.03894631117814
Zack CJ Fender EA Chandrashekar P Reddy YNV Bennett CE Stulak JM et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. (2017) 70:2953–60. 10.1016/j.jacc.2017.10.03929969002
Kawsara A Alqahtani F Nkomo VT Eleid MF Pislaru SV Rihal CS et al. Determinants of morbidity and mortality associated with isolated tricuspid valve surgery. J Am Heart Assoc. (2021) 10:e018417. 10.1161/JAHA.120.01841733399012
Hamandi M Smith RL Ryan WH Grayburn PA Vasudevan A George TJ et al. Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann Thorac Surg. (2019) 108:11–5. 10.1016/j.athoracsur.2019.03.00430951698
Nath J Foster E Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. (2004) 43:405–9. 10.1016/j.jacc.2003.09.03615013122
Chorin E Rozenbaum Z Topilsky Y Konigstein M Ziv-Baran T Richert E et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. (2020) 21:157–65. 10.1093/ehjci/jez21633157062
Wong WK Chen SW Chou AH Lee HA Cheng YT Tsai FC et al. Late outcomes of valve repair versus replacement in isolated and concomitant tricuspid valve surgery: a nationwide cohort study. J Am Heart Assoc. (2020) 9:e015637. 10.1161/JAHA.119.01563732301369
Vassileva CM Shabosky J Boley T Markwell S Hazelrigg S. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database. J Thorac Cardiovasc Surg. (2012) 143:1043–9. 10.1016/j.jtcvs.2011.07.00421872283
Kar S Mack MJ Lindenfeld J Abraham WT Asch FM Weissman NJ et al. Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT trial. Circulation. (2021) 144:426–37. 10.1161/CIRCULATIONAHA.120.05306134039025
O'Neill BP Negrotto S Yu D Lakhter V Depta J McCabe JM et al. Caval valve implantation for tricuspid regurgitation: insights from the united states caval valve registry. J Invasive Cardiol. (2020) 32:470–5.33087585
Toggweiler S De Boeck B Brinkert M Buhmann R Bossard M Kobza R et al. First-in-man implantation of the Tricento transcatheter heart valve for the treatment of severe tricuspid regurgitation. EuroIntervention. (2018) 14:758–61. 10.4244/EIJ-D-18-0044029969434
Lauten A Dreger H Schofer J Grube E Beckhoff F Jakob P et al. Caval valve implantation for treatment of severe tricuspid regurgitation. J Am Coll Cardiol. (2018) 71:1183–4. 10.1016/j.jacc.2017.12.05631929100
Sugiura A Tanaka T Kavsur R Oeztuerk C Vogelhuber J Wilde N et al. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge-to-edge tricuspid repair. JACC Cardiovasc Interv. (2021) 14:2260–70. 10.1016/j.jcin.2021.07.04834424200
Taramasso M Gavazzoni M Pozzoli A Dreyfus GD Bolling SF George I et al. Tricuspid regurgitation: predicting the need for intervention, procedural success, and recurrence of disease. JACC Cardiovasc Imaging. (2019) 12:605–21. 10.1016/j.jcmg.2018.11.03430947904
Fortuni F Butcher SC Dietz MF van der Bijl P Prihadi EA De Ferrari GM et al. Right ventricular-pulmonary arterial coupling in secondary tricuspid regurgitation. Am J Cardiol. (2021) 148:138–45. 10.1016/j.amjcard.2021.02.03733667451
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
